Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stéphane Depil1, Paola Bonaventura2, Vincent Alcazer2

  • 1Centre Léon-Bérard, 28, Prom. Léa-et-Napoléon-Bullukian, 69008 Lyon, France; Université Claude-Bernard-Lyon-1, 43, boulevard du 11-Novembre-1918, 69100 Villeurbanne, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy.

Journal for immunotherapy of cancer·2026
Same author

Shrouded in a starry sky: a case of AML-MRC with KMT2A amplification mimicking Burkitt-like morphology.

Blood·2026
Same author

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026
Same author

HLA diversity is associated with TKI response and treatment-free remission in chronic myeloid leukemia.

HemaSphere·2025
Same author

The pivotal role of immune functional assays in deciphering immune function alterations.

Clinical and experimental immunology·2025
Same author

HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer.

Journal for immunotherapy of cancer·2025

Next-generation cancer vaccines, utilizing personalized neoantigens, aim to improve tumor control by stimulating adaptive immune responses. While preclinical data is promising, clinical efficacy and optimal neoantigen selection require further research.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Cancer vaccines aim to induce adaptive immune responses against tumor antigens for long-term tumor control.
  • Early cancer vaccines yielded disappointing clinical results.
  • Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and neoantigens have revitalized cancer vaccine research.

Purpose of the Study:

  • To explore the potential of next-generation cancer vaccines based on personalized neoantigens.
  • To investigate the role of neoantigens in inducing potent anti-tumor T cell responses.
  • To assess the potential of cancer vaccines in combination with ICIs and in treating "cold tumors".

Main Methods:

  • Utilizing mutation-associated neoantigens specific to individual tumors for a personalized approach.
Keywords:
AdjuvantCheckpointsNeoantigensNéoantigènesVaccinVaccine

Related Experiment Videos

  • Preclinical studies to evaluate the induction of anti-tumor immune responses.
  • Ongoing clinical trials to assess efficacy and safety.

    • Main Results:

    • Preclinical studies demonstrate that neoantigens can induce potent anti-tumor immune responses due to the absence of thymic selection.
    • Clinical trials are underway with promising preliminary results.
    • The optimization of neoantigen selection remains a key challenge.

    Conclusions:

    • Next-generation cancer vaccines, particularly personalized neoantigen vaccines, show significant promise.
    • Further clinical validation is needed to demonstrate anti-tumor effects.
    • Cancer vaccines may enhance ICI therapy, treat "cold tumors", and be beneficial in adjuvant settings for residual disease control.